written on 30.06.2014

Myths and Misconceptions about Generic Competition still Prevalent


Five years ago, Thomson Reuters published a white paper about the five myths of generic competition that were prevalent at that time: The primary interest of generic companies is in products with sales in excess of $500 million Drug master files, ANDA filings and patent challenges are the first reliable signs of generic activity The […]